CTLA4 and neoplasm: Higher tumor mutation burden (TMB-H) has been viewed as a predictive biomarker for better responses of cancer patients to anti-PD-1 and anti-CTLA4 therapy, because the increasing numbers of mutant-protein-derived tumor antigens allow the enhanced immunogenicity [43].